Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 12Neoplasms 3Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Adenocarcinoma 1

Interventions

Ipilimumab 10tremelimumab 6durvalumab 5Nivolumab 3pembrolizumab 2tilsotolimod 1spartalizumab 1relatlimab 1folfirinox 1balstilimab 1Vemurafenib 1Vaccines 1Radiotherapy 1Radiofrequency Ablation 1Radiation 1Paclitaxel 1Oxaliplatin 1Opdualag 1Melphalan 1Leucovorin 1Fluorouracil 1Docetaxel 1Cryosurgery 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Diabetes Mellitus, Insulin-Dependent, 12 × folfirinox × Clear all
NCT01896869 2020-05-19

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
83 enrolled 16 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡